Jazz Pharmaceuticals plc Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Jazz Pharmaceuticals plc payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for the quarter ending 2025-09-30 was $23.00K, a 99.98% decline year-over-year.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for the quarter ending 2024-09-30 was $150.00M, a 101.69% increase year-over-year.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for fiscal 2025 was $125.02M, a 59.86% decline from fiscal 2024.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for fiscal 2024 was $311.43M, a 15.45% increase from fiscal 2023.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for fiscal 2023 was $269.76M, a 499457.41% increase from fiscal 2022.
- Jazz Pharmaceuticals plc payments for repurchase of common stock for fiscal 2022 was $54.00K.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $125.02M 10-K · filed 2026-02-24 |
| 2025-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $311.43M 10-K · filed 2026-02-24 |
| 2024-09-30 | $150.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2023-12-31 | $99.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $269.76M 10-K · filed 2026-02-24 |
| 2023-09-30 | $74.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $54.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $0.00 derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-04 | $7.48M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $146.54M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $256.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $7.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $276.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $139.05M 10-Q · filed 2021-05-04 | $329.25M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $110.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $301.45M 10-K · filed 2022-03-01 |
| 2019-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $637.77M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $59.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $639.23M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $111.25M 10-Q · filed 2020-05-05 | $600.38M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $446.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $523.67M 10-K · filed 2021-02-23 |
| 2018-09-30 | $21.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $119.39M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $21.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $123.50M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $34.55M 10-Q · filed 2019-05-07 | $119.45M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $42.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $98.80M 10-K · filed 2020-02-25 |
| 2017-09-30 | $25.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $74.90M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $16.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $145.91M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $13.90M 10-Q · filed 2018-05-08 | $157.83M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $18.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $278.30M 10-K · filed 2019-02-26 |
| 2016-09-30 | $96.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $300.07M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $28.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $213.11M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $134.37M 10-Q · filed 2017-05-09 | $185.58M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $40.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $61.55M 10-K · filed 2018-02-27 |
| 2015-09-30 | $9.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $33.54M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $30.42M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $10.34M 10-Q · filed 2016-05-10 | $52.55M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $42.22M 10-K · filed 2017-02-28 |
| 2014-09-30 | $6.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $64.06M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-06-30 | $23.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $106.39M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-07 | |
| 2013-12-31 | $34.09M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $136.48M 10-K · filed 2016-02-23 |
| 2013-09-30 | $48.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | |
| 2012-12-31 | $0.00 10-K · filed 2015-02-24 | |
| 2011-12-31 | $0.00 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |